Full-Time

Senior Regulatory Affairs Specialist

Hyperfine

Hyperfine

51-200 employees

Portable bedside MRI system for hospitals

Compensation Overview

$130k - $150k/yr

+ Bonus + Equity

No H1B Sponsorship

Palo Alto, CA, USA + 1 more

More locations: Branford, CT, USA

Hybrid

Hybrid role; must be on-site 3 days per week.

Category
Legal & Compliance (1)
Required Skills
Risk Management

Get referred to Hyperfine

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in a scientific or regulatory discipline, plus 8 years' experience in the medical device industry; or equivalent work experience.
  • Minimum 5 years' experience in Regulatory Affairs role.
  • History of successful regulatory clearances/approvals in global markets.
  • Thorough working knowledge of Quality System standards and regulations including but not limited to 21 CFR 820, ISO 13485, MDSAP, EU MDD/MDR, UKCA.
  • Thorough working knowledge of risk management and other standards including but not limited to ISO 14971, IEC 60601, and IEC 62304.
  • Extensive knowledge of regulatory strategy and approval approaches.
  • Strong knowledge of medical device labeling requirements.
  • Effective written and oral communication skills including the ability to interact with all levels of the company.
  • Proficient ability to read, analyze and interpret technical documents, professional journals, technical procedures, and regulations.
  • Ability to navigate effectively through the regulatory process as part of a team ensuring project and company success.
  • Detail-oriented, hands-on, proactive problem solver.
  • Ability to work with minimal supervision.
  • Experience interpreting FDA and international guidelines and regulations.
  • History of successful US FDA 510(k) clearances for Class II devices and interactions with regulators.
  • Experience with EU MDR, Health Canada, and Australia TGA regulatory submissions.
  • Experience with international registrations.
  • Proven track record of navigating swiftly and efficiently through the regulatory process as part of a team ensuring project and company success.
  • Experience hosting audits.
Desired Qualifications
  • Experience in Research & Development (R&D).
  • Familiarity with AI-based software, medical imaging, active devices.

Hyperfine creates medical imaging tools for hospitals, focusing on the Swoop system, the first FDA-cleared portable ultra-low field MRI that can image a patient’s brain at the bedside. How it works: a compact, portable MRI device is brought to the patient in settings like intensive care units, performing brain scans without moving the patient to a radiology suite. The open, safe design allows family members to stay nearby during imaging. Differentiation: it is already FDA-cleared and designed for point-of-care use, enabling bedside decision-making, faster treatment decisions, quicker discharges, and more efficient use of hospital staff and resources at a lower cost compared to traditional MRI workflows. Revenue model: Hyperfine sells the Swoop system and related services to hospitals, clinics, and other healthcare facilities. Goal: improve patient care by bringing diagnostic imaging directly to patients, increasing access to timely brain imaging and streamlining clinical workflows.

Company Size

51-200

Company Stage

IPO

Headquarters

Guilford, Connecticut

Founded

2014

Get referred to Hyperfine

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 83% to $3.9 million on stronger device sales.[2]
  • CE Mark, UKCA Mark, and India approval unlock broader international commercialization.[2]
  • PRIME data cut emergency scan start time by 6.35 hours versus conventional MRI.

What critics are saying

  • Revenue remains concentrated in brain imaging, limiting near-term expansion beyond one use case.[2][3]
  • Contrast-enhanced MRI submission is still pending, delaying the larger product-upgrade opportunity.
  • Hyperfine burned cash in Q1 2026 and remains dependent on external financing.[2]

What makes Hyperfine unique

  • Hyperfine sells the first FDA-cleared, portable, ultra-low-field brain MRI system.[1][3]
  • Swoop brings brain imaging to bedside settings like ICUs and emergency departments.[1][3]
  • Next-generation Swoop and Optive AI add better workflow and stroke imaging.[2]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Wellness Program

Mental Health Support

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

0%
The Associated Press
Apr 9th, 2026
Hyperfine wins CE and UKCA marks for next-gen Swoop MRI system and Optive AI software

Hyperfine has received CE marking and UK Conformity Assessment approval for its next-generation Swoop portable MRI system and latest Optive AI software, enabling commercialisation across Europe and the UK. The approvals mark a key milestone in the company's international growth strategy. The next-generation Swoop system, FDA-cleared in Q2 2025, delivers improved image quality and workflow for brain imaging. The updated Optive AI software includes multi-direction diffusion-weighted imaging capabilities, enhancing stroke detection similar to high-field MRI scanners. The technology is currently distributed across over a dozen European countries through Hyperfine's network. The company plans to begin commercialisation of the new system and software in Europe and the UK in early Q3 2026, ahead of internal expectations.

Yahoo Finance
Mar 19th, 2026
Hyperfine reports $5.3M Q4 revenue, up 128%, targets $21M in 2026 with 50%+ margins

Hyperfine Inc reported record fourth-quarter revenue of $5.3 million, up 128% year-over-year, driven by strong performance of its next-generation Swoop scanner. The medical imaging company sold 16 units in Q4, compared to nine units in the prior-year period. Gross margin expanded to 50.9%, up 1,530 basis points from Q4 2024, whilst net loss narrowed to $5.9 million from $10.4 million. Full-year 2025 revenue reached $13.6 million, up 5% from 2024. The company received FDA clearance for updated Optive AI software and gained approval for its first-generation Swoop system in India. Hyperfine reduced cash burn by 30% year-over-year to $5.7 million. For 2026, the company projects revenue of $20 million to $22 million, representing 55% growth at the midpoint, with gross margins of 50% to 55%.

Yahoo Finance
Mar 18th, 2026
Hyperfine reports $5M Q4 revenue as portable brain MRI gains traction in hospitals

Hyperfine reported fourth-quarter revenue exceeding $5 million, driven by accelerating adoption of its second-generation Swoop portable brain MRI system and Optive AI software. CEO Maria Sainz described the combination as a "market turning point" for portable brain MRI, highlighting diagnostic-quality imaging from ultra-low field magnets. The company has sold over a dozen next-generation systems since June 2025, focusing on critical care, emergency departments and neurology offices. The FDA cleared a software update in December 2025 featuring diffusion-weighted imaging for stroke workflows. Hyperfine cited external validation including published health economic data from Jefferson Abington Hospital showing cost savings across 143 scans. Yale School of Medicine's PRIME study evaluating AI-powered portable MRI in emergency departments completed enrollment ahead of schedule, with results expected later in 2026.

Stock Titan
Mar 18th, 2026
Hyperfine (NASDAQ: HYPR) adds $40M loan facility and over 1.0M stock warrants

Hyperfine arranged a $40M senior secured loan with Horizon, drawing $15M initially, at a minimum 10.75% rate and issuing over 1.0M stock warrants at $1.20 per share.

Business Wire
Nov 20th, 2025
Hyperfine Awarded $3.7 Million Grant to Advance Global Brain Health

$3.7M grant supports expanded use of portable MRI to evaluate brain development and guide targeted health interventions in underserved communities.